Hui-Ju Han

Ms. Hui-Ju Han

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2018 in Viruses
Verified
Journal Article
Open access
PDF file
HHHui-Ju Han
Hui-Ju Han
JLJian-Wei Liu
Jian-Wei Liu
HYHao Yu
Hao Yu
XYXue-Jie Yu
Xue-Jie Yu
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection.

1 May 2019 in Acta Tropica
Verified
Journal Article
Closed access
LWLi-Jun Wang
Li-Jun Wang
HHHui-Ju Han
Hui-Ju Han
MZMin Zhao
Min Zhao
JLJian-Wei Liu
Jian-Wei Liu
LLLimei Luo
Limei Luo
XYXue-Jie Yu
Xue-Jie Yu